Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL
Published in New England Journal of Medicine
Methodology
Human phosphatidylcholine challenge studies plus prospective cohort measuring trimethylamine N-oxide and cardiovascular events
Key Findings
Dietary phosphatidylcholine was metabolized by gut microbiota to TMAO, and higher fasting TMAO levels predicted increased risk of major adverse cardiovascular events
Conclusions
Phosphatidylcholine intake raises TMAO, a biomarker associated with cardiovascular risk
Limitations
Association does not establish that supplemental phosphatidylcholine causes cardiovascular events
Supplements Studied
Dietary phosphatidylcholine was metabolized by gut microbiota to TMAO, and higher fasting TMAO levels predicted increased risk of major adverse cardiovascular events
Outcomes Measured
Dietary phosphatidylcholine was metabolized by gut microbiota to TMAO, and higher fasting TMAO levels predicted increased risk of major adverse cardiovascular events
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.